Krsnaa Diagnostics Board Reshuffles: 2 Directors In, 3 Out, New Interim CFO
BOARD
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 17 Apr 2026, 04:46 PM IST · BSE ID: a2f957aa-ce93-4551-b084-38785d040e9c
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's Board replaced three departing directors with two new independent directors and an interim finance chief, pending shareholder approval.
🤖 AI Summary
- Board approves appointment of Raju Venkatraman and Lilian Jessie Paul as Independent Directors for two-year terms
- Chetan Desai reappointed as Independent Director for five consecutive years through April 24, 2031
- Chandra Prakash Singh appointed as Interim Chief Financial Officer effective April 17, 2026
- Three directors complete tenure: Pallavi Bhatevara (Whole-time), Rajiva Ranjan Verma, Chhaya Palrecha (Independent) exiting April 24-25
- All appointments and exits subject to shareholder postal ballot approval as required by SEBI
🔢 Key Numbers — exact figures from BSE filing, not rounded
Raju Venkatraman appointment term
2 years (April 25, 2026 to April 24, 2028)
Lilian Jessie Paul appointment term
2 years (April 25, 2026 to April 24, 2028)
Chetan Desai reappointment term
5 years (April 25, 2026 to April 24, 2031)
Interim CFO effective date
April 17, 2026
🏢 How This Affects the Company
Three directors complete tenure and exit April 24-25, 2026. Two new independent directors join April 25 with entrepreneurial and operational experience. New Interim CFO Chandra Prakash Singh assumes financial stewardship from April 17, 2026, until permanent CFO appointment.
Interim CFO status introduces continuity risk in financial management pending permanent appointment. Loss of three directors within 24-hour window creates near-term governance transition.
👥 What This Means For Shareholders
✅
Action Required
Shareholders must vote in postal ballot to approve all four Board changes before implementation takes effect.
👤
Who Is Affected
All shareholders must participate in postal ballot. Directors and committee compositions change April 24-25, affecting Board representation and governance structure.
🔍
Management Signal
Management prioritizes governance strengthening through selective director replacement while retaining continuity via Desai's extended tenure.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Postal ballot result filing — track shareholder approval of Board appointments within 30 days
Permanent CFO appointment filing — monitor when Chandra Prakash Singh's interim tenure concludes and successor named
Q1 FY27 results — assess financial reporting quality and audit committee effectiveness under new composition
MEDIUM RISK
Interim CFO role introduces financial continuity risk. Three simultaneous director exits compress governance transition. Postal ballot approval remains pending.
💡 Investor Takeaway
Board restructuring approved with two new independent directors and five-year reappointment of Chetan Desai, offset by three simultaneous director exits April 24-25, 2026. Interim CFO fills leadership gap pending permanent hire. All changes contingent on shareholder postal ballot approval.
⚖️ Strengths & Concerns
✅ Positives
- Chetan Desai reappointed for extended five-year term signals Board stability and confidence in his leadership.
- Two new independent directors bring entrepreneurial and operational experience, enhancing Board governance depth.
⚠️ Concerns
- Interim CFO appointment indicates unplanned departure or vacancy, creating temporary financial leadership uncertainty.
- Three director exits within 24 hours (April 24-25) creates compressed governance transition period requiring rapid integration.
📅 Company Track Record
Krsnaa Diagnostics is a diagnostic services company listed on BSE. No prior financial data or performance metrics provided in past filings context.
Based on publicly available historical data. For context only.